← Russell 3000 cross-section

CORT CORCEPT THERAPEUTICS INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$12.9bn
Revenue TTM
$831m
Net income TTM
$55m
Free cash flow
$107m
Composite score
39.0
Sector rank
#604

Valuation

P / E
233.9
EV / EBITDA
1,492.0
EV / sales
15.2
FCF yield
0.83%
Earnings yield vs 10-yr
-4.30pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
6.6%
EBITDA margin
1.0%
ROE
7.8%
ROIC
1.6%
Revenue growth
16.0%

Insider activity, last 90 days

Net open-market
$-57.27m
Buyers
0
Sellers
9

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net product revenue was $256.1 million and $421.1 million for the three and six months ended June 30, 2026, respectively, compared to $194.4 million and $351.6 million for the comparable periods in 2025. The increases were driven by higher net product revenue from our Hypercortisolism Products and net product revenue from Lifyorli. Net product revenue from our Hypercortisolism Products was $208.6 million and $373.5 million for the three and six months ended June 30, 2026, respectively, compared to $194.4 million and $351.6 million for the comparable periods in 2025. …CORCEPT THERAPEUTICS INC, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →